Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Berlex’ Yaz Gains Indication For Premenstrual Dysphoric Disorder

This article was originally published in The Pink Sheet Daily

Executive Summary

The oral contraceptive is the first approved for the treatment of emotional and physical symptoms of PMDD.
Advertisement

Related Content

Bayer Puts Marketing Muscle Behind Yaz
Bayer Puts Marketing Muscle Behind Yaz
Bayer, Intendis To Copromote Yaz For Acne/Birth Control Indication
Berlex’s Yaz Gains Acne Indication
Schering AG Sales BENEFIT From Betaseron Study
Merck KgaA Steps Aside For Bayer/Schering Merger To Move Forward
Berlex' Yaz Launch To Proceed Despite Patent Suit
Berlex’ YAZ Clears FDA For Contraception; April Launch Planned
Berlex’ YAZ Clears FDA For Contraception; April Launch Planned
Loestrin 24 Approved As First 24-Day Oral Contraceptive

Topics

Advertisement
UsernamePublicRestriction

Register

PS063315

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel